MedPath

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Phase 1
Recruiting
Conditions
B-cell Malignancy
Relapsed Cancer
Refractory Cancer
B-cell Lymphoma
Interventions
Registration Number
NCT06634589
Lead Sponsor
BeiGene
Brief Summary

The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies. This study currently includes four substudies, and more substudies may be added as other combination agents are identified.

Detailed Description

This new study will check how safe and helpful a potential anticancer drug called BGB-16673 is in participants with R/R B-cell malignancies when it is given in combination with other medicines - sonrotoclax in substudy 1, zanubrutinib in substudy 2, mosunetuzumab in substudy 3, and glofitamab in substudy 4.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
80
Inclusion Criteria
  • Must sign the informed consent form (ICF) and be capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the ICF

  • Confirmed diagnosis of a R/R B-cell malignancy

  • Protocol-defined measurable disease

  • Stable Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2

  • Adequate organ function

  • Female participants of childbearing potential must be willing to use a highly effective method of birth control and refrain from egg donation for the duration of the study and for 30 days after the last dose of BGB-16673 or zanubrutinib, 60 days after the last dose of glofitamab, or 90 days after the last dose of sonrotoclax or mosunetuzumab. A negative urine or serum pregnancy test result must be provided 10-14 days before the first dose of study treatment

  • Nonsterile male participants must be willing to use a highly effective method of birth control and refrain from sperm donation for the duration of the study and for 30 days after the last dose of BGB-16673 or zanubrutinib, 60 days after the last dose of glofitamab, or 90 days after the last dose of sonrotoclax or mosunetuzumab

  • Substudies 1, 3, and 4 Inclusion Criterion:

    • Adequate renal function as indicated by estimated glomerular filtration rate (eGFR) of ≥ 50 mL/min
  • Substudy 2 Inclusion Criteria:

    • Bruton tyrosine kinase (BTK) inhibitor-naive, or previously received treatment with a covalent BTK inhibitor and discontinued for reasons other than clinical progression
    • Adequate renal function as indicated by eGFR of ≥ 30 mL/min

Key

Exclusion Criteria
  • Treatment-naive B-cell malignancies

  • Unable to comply with the requirements of the protocol

  • Active leptomeningeal disease or uncontrolled, untreated brain metastasis

  • Any malignancy ≤ 2 years before first dose of study treatment except for the specific cancer under investigation in this study or any locally recurring cancer that has been treated curatively

  • Autologous stem cell transplant ≤ 3 months prior to screening or chimeric antigen T-cell therapy ≤ 3 months prior to screening

  • Substudies 1 and 2: Prior allogeneic stem cell transplant with active graft-versus-host disease (GVHD), or requiring immunosuppressive drugs for treatment of GVHD, or who have taken calcineurin inhibitors within 4 weeks prior to consent

  • Participants who have a history of severe allergic reactions or hypersensitivity to the active ingredient and excipients of BGB-16673, sonrotoclax, zanubrutinib, mosunetuzumab, or glofitamab

  • Substudy 1 Exclusion Criterion:

    • Prior treatment with a B-cell lymphoma-2 (Bcl-2) inhibitor (with exception for participants who relapsed ≥ 24 months after completion of a full course of a prior Bcl-2 inhibitor containing regimen)
  • Substudy 2 Exclusion Criterion:

    • Participants who discontinued prior zanubrutinib treatment due to intolerance
  • Substudies 3 and 4 Exclusion Criteria:

    • Prior exposure to a CD20 x CD3 T-cell engager antibody treatment
    • All participants with a prior allogeneic stem cell transplant

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Substudy 1 Part 1a: Dose EscalationBGB-16673Sequential cohorts of increasing dose level combinations of BGB-16673 and sonrotoclax will be evaluated in participants with selected B-cell malignancies.
Substudy 1 Part 1a: Dose EscalationSonrotoclaxSequential cohorts of increasing dose level combinations of BGB-16673 and sonrotoclax will be evaluated in participants with selected B-cell malignancies.
Substudy 1 Part 1b: Safety ExpansionBGB-16673Cohorts of select dose level combinations of BGB-16673 and sonrotoclax will be evaluated in participants with selected B-cell malignancies.
Substudy 1 Part 1b: Safety ExpansionSonrotoclaxCohorts of select dose level combinations of BGB-16673 and sonrotoclax will be evaluated in participants with selected B-cell malignancies.
Substudy 2 Part 1a: Dose EscalationBGB-16673Sequential cohorts of increasing dose level combinations of BGB-16673 and zanubrutinib will be evaluated in participants with selected B-cell malignancies.
Substudy 2 Part 1a: Dose EscalationZanubrutinibSequential cohorts of increasing dose level combinations of BGB-16673 and zanubrutinib will be evaluated in participants with selected B-cell malignancies.
Substudy 2 Part 1b: Safety ExpansionBGB-16673Cohorts of select dose level combinations of BGB-16673 and zanubrutinib will be evaluated in participants with selected B-cell malignancies.
Substudy 2 Part 1b: Safety ExpansionZanubrutinibCohorts of select dose level combinations of BGB-16673 and zanubrutinib will be evaluated in participants with selected B-cell malignancies.
Substudy 3 Part 1a: Dose EscalationBGB-16673Sequential cohorts of increasing dose level combinations of BGB-16673 and mosunetuzumab will be evaluated in participants with selected B-cell malignancies.
Substudy 3 Part 1a: Dose EscalationMosunetuzumabSequential cohorts of increasing dose level combinations of BGB-16673 and mosunetuzumab will be evaluated in participants with selected B-cell malignancies.
Substudy 3 Part 1b: Safety ExpansionBGB-16673Cohorts of select dose level combinations of BGB-16673 and mosunetuzumab will be evaluated in participants with selected B-cell malignancies.
Substudy 3 Part 1b: Safety ExpansionMosunetuzumabCohorts of select dose level combinations of BGB-16673 and mosunetuzumab will be evaluated in participants with selected B-cell malignancies.
Substudy 4 Part 1a: Dose EscalationBGB-16673Sequential cohorts of increasing dose level combinations of BGB-16673 and glofitamab will be evaluated in participants with selected B-cell malignancies. Participants will receive obinutuzumab as pretreatment prior to the start of combination treatment.
Substudy 4 Part 1a: Dose EscalationGlofitamabSequential cohorts of increasing dose level combinations of BGB-16673 and glofitamab will be evaluated in participants with selected B-cell malignancies. Participants will receive obinutuzumab as pretreatment prior to the start of combination treatment.
Substudy 4 Part 1a: Dose EscalationObinutuzumabSequential cohorts of increasing dose level combinations of BGB-16673 and glofitamab will be evaluated in participants with selected B-cell malignancies. Participants will receive obinutuzumab as pretreatment prior to the start of combination treatment.
Substudy 4 Part 1b: Safety ExpansionBGB-16673Cohorts of select dose level combinations of BGB-16673 and glofitamab will be evaluated in participants with selected B-cell malignancies.
Substudy 4 Part 1b: Safety ExpansionGlofitamabCohorts of select dose level combinations of BGB-16673 and glofitamab will be evaluated in participants with selected B-cell malignancies.
Substudy 4 Part 1b: Safety ExpansionObinutuzumabCohorts of select dose level combinations of BGB-16673 and glofitamab will be evaluated in participants with selected B-cell malignancies.
Primary Outcome Measures
NameTimeMethod
Substudy 3 Part 1b: Number of participants with treatment-emergent adverse events, treatment-related adverse events, and serious adverse eventsFrom the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years]
Substudy 4 Part 1a: Number of participants with dose-limiting toxicities (DLTs), treatment-emergent adverse events, treatment-related adverse events, and serious adverse eventsFrom the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years
Substudy 4 Part 1b: Number of participants with treatment-emergent adverse events, treatment-related adverse events, and serious adverse eventsFrom the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years
Substudy 1 Part 1a: Number of participants with dose-limiting toxicities (DLTs), treatment-emergent adverse events, treatment-related adverse events, and serious adverse eventsFrom the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years
Substudy 1 Part 1b: Number of participants with treatment-emergent adverse events, treatment-related adverse events, and serious adverse eventsFrom the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years
Substudy 2 Part 1a: Number of participants with dose-limiting toxicities (DLTs), treatment-emergent adverse events, treatment-related adverse events, and serious adverse eventsFrom the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years
Substudy 2 Part 1b: Number of participants with treatment-emergent adverse events, treatment-related adverse events, and serious adverse eventsFrom the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years
Substudy 3 Part 1a: Number of participants with dose-limiting toxicities (DLTs), treatment-emergent adverse events, treatment-related adverse events, and serious adverse eventsFrom the first dose of study drug(s) to 30 days after the last dose; up to approximately 2 years
Secondary Outcome Measures
NameTimeMethod
Substudy 1 Parts 1a and 1b: Overall Response Rate (ORR) in participants with B-cell malignanciesUp to approximately 3 years

ORR is defined as the percentage of participants with complete response (CR) or partial response (PR) as assessed by investigator.

Substudy 1 Parts 1a and 1b: Time to Response (TTR)Up to approximately 3 years

TTR is defined as the time from treatment initiation to first documented response.

Substudy 1 Part 1a: Area under the plasma concentration-time curve (AUC) of BGB-16673 and sonrotoclaxFrom Week 1 to Week 17
Substudy 1 Part 1a: Maximum observed concentration (Cmax) of BGB-16673 and sonrotoclaxFrom Week 1 to Week 17
Substudy 1 Part 1a: Time to maximum concentration (Tmax) of BGB-16673 and sonrotoclaxFrom Week 1 to Week 17
Substudy 1 Part 1a: Terminal half-life (t1/2) of BGB-16673 and sonrotoclaxFrom Week 1 to Week 17
Substudy 2 Parts 1a and 1b: ORR in participants with B-cell malignanciesUp to approximately 3 years

ORR is defined as the percentage of participants with complete response (CR) or partial response (PR) as assessed by the investigator.

Substudy 1 Parts 1a and 1b: Trough concentration (Ctrough) of BGB-16673 and sonrotoclaxFrom Week 1 to Week 17
Substudy 2 Parts 1a and 1b: TTRUp to approximately 3 years

TTR is defined as the time from treatment initiation to the first documented response.

Substudy 2 Part 1a: Area under the plasma concentration-time curve (AUC) of BGB-16673 and zanubrutinibFrom Week 1 to Week 17
Substudy 2 Part 1a: Maximum observed concentration (Cmax) of BGB-16673 and zanubrutinibFrom Week 1 to Week 17
Substudy 2 Part 1a: Time to maximum concentration (Tmax) of BGB-16673 and zanubrutinibFrom Week 1 to Week 17
Substudy 3 Parts 1a and 1b: DORUp to approximately 3 years

DOR is defined as the time from the first documented response to documented disease progression or death, whichever occurs first.

Substudy 3 Parts 1a and 1b: TTRUp to approximately 3 years

TTR is defined as the time from treatment initiation to the first documented response.

Substudy 3 Part 1a: Area under the plasma concentration-time curve (AUC) of BGB-16673 and mosunetuzumabFrom Week 1 to Week 12
Substudy 3 Part 1a: Maximum observed concentration (Cmax) of BGB-16673 and mosunetuzumabFrom Week 1 to Week 12
Substudy 3 Part 1a: Time to maximum concentration (Tmax) of BGB-16673 and mosunetuzumabFrom Week 1 to Week 12
Substudy 3 Part 1a: Terminal half-life (t1/2) of BGB-16673 and mosunetuzumabFrom Week 1 to Week 12
Substudy 3 Parts 1a and 1b: Trough concentration (Ctrough) of BGB-16673 and mosunetuzumabFrom Week 1 to Week 36
Substudy 4 Parts 1a and 1b: ORR in participants with B-cell malignanciesUp to approximately 3 years

ORR is defined as the percentage of participants with partial response (PR) or better as assessed by the investigator.

Substudy 4 Parts 1a and 1b: DORUp to approximately 3 years

DOR is defined as the time from the first documented response to documented disease progression or death, whichever occurs first.

Substudy 4 Parts 1a and 1b: TTRUp to approximately 3 years

TTR is defined as the time from treatment initiation to the first documented response.

Substudy 4 Part 1a: Area under the plasma concentration-time curve (AUC) of BGB-16673From Week 1 to Week 10
Substudy 4 Part 1a: Maximum observed concentration (Cmax) of BGB-16673From Week 1 to Week 10
Substudy 4 Part 1a: Time to maximum concentration (Tmax) of BGB-16673From Week 1 to Week 10
Substudy 4 Part 1a: Terminal half-life (t1/2) of BGB-16673From Week 1 to Week 10
Substudy 4 Parts 1a and 1b: Trough concentration (Ctrough) of BGB-16673From Week 1 to Week 10
Substudy 1 Parts 1a and 1b: Duration of Response (DOR)Up to approximately 3 years

DOR is defined as the time from the first documented response to documented disease progression or death, whichever occurs first.

Substudy 2 Part 1a: Terminal half-life (t1/2) of BGB-16673 and zanubrutinibFrom Week 1 to Week 17
Substudy 2 Parts 1a and 1b: Trough concentration (Ctrough) of BGB-16673 and zanubrutinibFrom Week 1 to Week 17 for Part 1a; From Week 1 to Week 5 for Part 1b
Substudy 1 Part 1b: Number of patients with complete response or complete response with incomplete count recovery (CR/CRi) who achieve undetectable minimal residual disease (uMRD)Up to approximately 3 years
Substudy 3 Parts 1a and 1b: ORR in participants with B-cell malignanciesUp to approximately 3 years

ORR is defined as the percentage of participants with complete response (CR) or partial response (PR) as assessed by the investigator.

Substudy 2 Parts 1a and 1b: DORUp to approximately 3 years

DOR is defined as the time from the first documented response to documented disease progression or death, whichever occurs first.

Trial Locations

Locations (49)

Hospital Sirio Libanes Brasilia

🇧🇷

Brasilia, Brazil

Ensino E Terapia de Inovacao Clinica Amo Etica

🇧🇷

Salvador, Brazil

Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto

🇧🇷

Sao Jose Do Rio Preto, Brazil

Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein

🇧🇷

Sao Paulo, Brazil

Mayo Clinic Phoenix

🇺🇸

Phoenix, Arizona, United States

University of Southern Californianorris Comprehensive

🇺🇸

Los Angeles, California, United States

Mayo Clinic Jacksonville

🇺🇸

Jacksonville, Florida, United States

Moffitt Cancer Center

🇺🇸

Tampa, Florida, United States

The University of Kansas Cancer Center

🇺🇸

Westwood, Kansas, United States

Mayo Clinic Rochester

🇺🇸

Rochester, Minnesota, United States

Scroll for more (39 remaining)
Hospital Sirio Libanes Brasilia
🇧🇷Brasilia, Brazil
© Copyright 2025. All Rights Reserved by MedPath